POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
Enrollment in PNT2002’s SPLASH trial is complete and topline data is expected in the fourth…
Enrollment in PNT2002’s SPLASH trial is complete and topline data is expected in the fourth…
Enrollment in PNT2002’s SPLASH trial is complete and topline data is expected in the fourth…
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early…
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early…
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage…
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage…
Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase…
Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase…
Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4,…
Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4,…
Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory…
Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory…
Data from first adult patient dosed in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated…
Data from first adult patient dosed in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated…
LONDON and DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) — Spectral MD Holdings, Ltd. (AIM: SMD), an artificial…
LONDON and DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) — Spectral MD Holdings, Ltd. (AIM: SMD), an artificial…
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia B…
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia B…
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V….
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V….